Rheumatoid Arthritis Therapeutics Market

Rheumatoid Arthritis Therapeutics Market by Molecules (Pharmaceuticals [NSAIDs, Analgesics, DMARDs, and Glucocorticoids] and Biopharmaceuticals [Biologics {TNF-α Antagonists, T-cell Inhibitors, CD20 Antigen, JAK Inhibitors, and Anti-IL6 Biologics} and Biosimilars {CD20 Antigen and TNF-α Antagonists}]), Sales Channel (Prescription and Over-the-Counter), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

  • Report ID: HC-1961
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 216
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global rheumatoid arthritis therapeutics market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of arthritis, improved treatment methods, favorable government initiatives, and rising awareness among the population.

Rheumatoid Arthritis Therapeutics Market

Rheumatoid arthritis (RA) is basically an immune system malfunctioning, a blistering condition that causes ongoing torment, expanding, and disaster in the functioning capacity of joints. It significantly occurs when a person’s immune system attacks his own cells of synovium. The synovium is inside coating of layers which fundamentally covers or protects the joints. The destruction of synovium causes pain in the joints and difficulty in movement. The symptoms of RA includes stiffness in joints, aching or pain in more than one joint, swelling and tenderness in joints, fever, fatigue or tiredness, weight loss, and weakness. RA can impact other tissues of the body and cause disorders in organs such as the heart, lungs, and eyes. The risk factors for RA are obesity, smoking, genetic inheritance, and old age.

According to the Centre for Disease Control and Prevention (CDC), in 2013–2015, around 54 million US adults, which was 22.7% of total population per year suffered from some kind of arthritis, lupus, rheumatoid arthritis, gout, or fibromyalgia. The same report estimated that till 2040, an around 78 million, representing 26% of US adults of age 18 years or more are projected to get diagnosed with arthritis. This high prevalence rate is likely boost the market in the near future.

The COVID-19 pandemic has brought huge impact on global market with restrictions and nationwide lockdowns worldwide. The RA market also witnessed negative impact due to the high burden of the coronavirus cases on the healthcare sector and reduced focus on other disease treatment as well as management. This market gained some momentum back with relaxing restriction and improving healthcare sector after the pandemic as government began to bolster their healthcare for the future events.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing demand for biologics along with rising numbers of generic drugs and FDA approvals for the treatment of rheumatoid arthritis is propelling the market growth. 
  • High prevalence of the disease, increasing governments support, and management of disease along with surge in flow of funding for research and development activities are driving the overall market growth.  
  • Favorable reimbursement policies, robust clinical pipeline, and well developed healthcare infrastructure are the key factors expected to boost the market expansion in the coming future.
  • High cost of biologics and accessibility to these biologics are key factors likely to hinder the market growth in the upcoming years.
  • Lack of proper healthcare facilities in some poor countries, low research activities and approval rate in the underdeveloped nations can be major restraints to the market.
  • Large untapped population, high prevalence of the disease, and increasing health awareness among the population prove to be creating a huge opportunity in the market expansion during the forecast period.

Scope of the Report

The report on the global rheumatoid arthritis therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Rheumatoid Arthritis Therapeutics  Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Molecules (Pharmaceuticals [NSAIDs, Analgesics, DMARDs, and Glucocorticoids] and Biopharmaceuticals [Biologics {TNF-α Antagonists, T-cell Inhibitors, CD20 Antigen, JAK Inhibitors, and Anti-IL6 Biologics} and Biosimilars {CD20 Antigen and TNF-α Antagonists}]), Sales Channel (Prescription and Over-the-Counter)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

AbbVie; Boehringer Ingelheim GmbH; Novartis International AG; Regeneron Pharmaceuticals, Inc.; Pfizer Inc.; Bristol-Myers Squibb.; Hoffmann-La Roche AG; UCB S.A.; Johnson & Johnson.; and Amgen Inc.

Market Segment Insights

Biopharmaceutical segment is expected to grow at a rapid pace

Based on molecules, the global rheumatoid arthritis therapeutics market is bifurcated into pharmaceutical and biopharmaceutical. The pharmaceutical segment is further divided into NSAIDS, analgesics, DMARDs, and glucocorticoids. The biopharmaceutical segment is sub-classified into biologics and biosimilars. The biologics segment is further segmented into TNF-α antagonists, T-cell inhibitors, CD20 antigen, JAK inhibitors, and anti-IL6 biologics. Additionally, the biosimilars segment is bifurcated into CD20 antigen and TNF-α antagonists. The biopharmaceutical segment is expected to grow at a rapid pace during the forecast period attributing to the high efficiency of the treatment. The biologics are more in demand than the biosimilars as the doctors prefer biologics.

Biologic drugs are anticipated to hold a major revenue share in developed markets in the coming future. However, in developing economies such as Mexico, Brazil, and South Africa, these drugs face several challenges from pharmaceutical generics and biosimilars due to expensive biologics in the market. The biosimilars segment is expected to exhibit a considerable growth rate in the near future as these drugs are cheap, easily available, and demonstrate high efficiency in terms of results. Due to launch of new products in the segment, biosimilars are gaining popularity in the developed nations as well and the developing nations are preferring biosimilars due to its cheap price. The pharmaceutical segment is the first-line of treatment for RA. So, this segment is also growing at a good pace. With new developments and technological advancement in the segment the market is set to grow at considerable rate.

Rheumatoid Arthritis Therapeutics Market

Prescription segment is projected to expand at a considerable CAGR

On the basis of sales channel, the market is bifurcated into prescription and over-the-counter (OTC). The prescription segment is projected to expand at a considerable CAGR owing to the growing awareness among the people regarding the need of prescribed by the doctor to avoid worsening of the disease or side-effect of the drugs. As prolonged use of RA drugs sometimes results in drug resistance, due to which patients suffering from this disease are expected to consult rheumatologists and follow prescribed drugs. Moreover, there are inadequate number of OTC products available, which makes the prescribed drugs to dominate in the coming future.

The OTC products has various disadvantages which is proving to be working in the negative direction for the segment. The OTC drugs have various adverse effects if used for long term as well as there are new drug development in the field with less side effects. So these factors are affecting the market segment in future market growth.

Rheumatoid Arthritis Therapeutics Market

North America is anticipated to constitute a major market share

In terms of regions, the global rheumatoid arthritis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to constitute a major market share in the coming years. Improved awareness of disease therapies among patients, rising prevalence of RA, and high public and non-government organization on healthcare expenditure are pushing the growth of the regional market. Additionally, favorable reimbursement policies, easy access to quality healthcare, strong clinical pipeline, and approval of novel drugs are anticipated to encourage the overall revenue share of North America.

Meanwhile, Asia Pacific is a promising region for substantial growth during the forecast period. The huge population and changing lifestyle of a large number of population are proving to be key factors for high spending on healthcare. Along with new product developments, the rising healthcare expenses is boosting the regional market growth in the near future.

Rheumatoid Arthritis Therapeutics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rheumatoid Arthritis Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Rheumatoid Arthritis Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Rheumatoid Arthritis Therapeutics Market - Supply Chain
  4.5. Global Rheumatoid Arthritis Therapeutics Market Forecast
     4.5.1. Rheumatoid Arthritis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Rheumatoid Arthritis Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Rheumatoid Arthritis Therapeutics Market Absolute $ Opportunity
5. Global Rheumatoid Arthritis Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Rheumatoid Arthritis Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Rheumatoid Arthritis Therapeutics Demand Share Forecast, 2019-2026
6. North America Rheumatoid Arthritis Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Rheumatoid Arthritis Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Rheumatoid Arthritis Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Rheumatoid Arthritis Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Rheumatoid Arthritis Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Rheumatoid Arthritis Therapeutics Demand Share Forecast, 2019-2026
8. Europe Rheumatoid Arthritis Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Rheumatoid Arthritis Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Rheumatoid Arthritis Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Rheumatoid Arthritis Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Rheumatoid Arthritis Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Rheumatoid Arthritis Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Rheumatoid Arthritis Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Rheumatoid Arthritis Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Rheumatoid Arthritis Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Rheumatoid Arthritis Therapeutics Market: Market Share Analysis
  11.2. Rheumatoid Arthritis Therapeutics Distributors and Customers
  11.3. Rheumatoid Arthritis Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. AbbVie Boehringer Ingelheim GmbH Novartis International AG Regeneron Pharmaceuticals, Inc. Pfizer Inc. Bristol-Myers Squibb.

Segments Covered in the Report

The global rheumatoid arthritis therapeutics market has been segmented on the basis of

Molecules

  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
      • TNF-α Antagonists
      • T-cell Inhibitors
      • CD20 Antigen
      • JAK Inhibitors
      • Anti-IL6 Biologics
    • Biosimilars
      • CD20 Antigen
      • TNF-α Antagonists

Sales channel

  • Prescription
  • Over-the-Counter

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • AbbVie
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb.
  • Hoffmann-La Roche AG
  • UCB S.A.
  • Johnson & Johnson.
  • Amgen Inc.

Key players competing in the global rheumatoid arthritis therapeutics market are Novartis International AG; AbbVie; Boehringer Ingelheim GmbH; Pfizer Inc.; Bristol-Myers Squibb.; Regeneron Pharmaceuticals, Inc.; Hoffmann-La Roche AG; UCB S.A.; Johnson & Johnson.; and Amgen Inc.

In January 2018, Glenmark pharmaceuticals received approval for Humira biosimilar to be operational in India.  Biosimilars of Adalimumab, Rituximab, and Infliximab have received regulatory approval for operating in some countries.

Rheumatoid Arthritis Therapeutics Market

Buy Report